Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Adicionar filtros








Intervalo de ano
1.
Journal of Central South University(Medical Sciences) ; (12): 1457-1463, 2020.
Artigo em Inglês | WPRIM | ID: wpr-880607

RESUMO

Antipsychotic medication is the primary treatment for schizophrenia, which is effective on ameliorating positive symptoms and can reduce the risk of recurrence, but it has limited efficacy for negative symptoms and cognitive dysfunction. The negative symptoms and cognitive dysfunction seriously affects the life quality and social function for the patients with schizophrenia. Currently, there is plenty evidence that antipsychotic drugs combined with adjuvant therapy drugs can effectively improve the negative symptoms and cognitive dysfunction. These drugs include anti-oxidants, nicotinic acetylcholine receptors and neuro-inflammatory drugs (anti-inflammatory drugs, minocycline), which show potential clinical effects.


Assuntos
Humanos , Anti-Inflamatórios/uso terapêutico , Antipsicóticos/uso terapêutico , Disfunção Cognitiva/etiologia , Minociclina/uso terapêutico , Esquizofrenia/tratamento farmacológico
2.
Journal of Central South University(Medical Sciences) ; (12): 701-705, 2019.
Artigo em Chinês | WPRIM | ID: wpr-813247

RESUMO

The negative symptoms and cognitive symptoms of schizophrenia patients are still clinical problems to be solved. Schizophrenia patients are abnormal in oxidative stress, immune regulation, and anti-histone deacetylase (HDAC), while sulforaphane plays a role in anti-oxidative stress, anti-inflammation, and anti-HDAC. Therefore, the sulforaphane could improve the negative symptoms and cognitive deficits of schizophrenia.


Assuntos
Humanos , Cognição , Isotiocianatos , Usos Terapêuticos , Esquizofrenia , Tratamento Farmacológico
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA